Patients with Chronic Myeloid Leukemia Diagnosed with Predominant Thrombocytosis without Marked Leukocytosis: Case Series

Fatih Yaman; Filiz Yavaşoğlu; Neslihan Andıc; Eren Gunduz; Hava Üsküdar Teke

Article Details

Patients with Chronic Myeloid Leukemia Diagnosed with Predominant Thrombocytosis without Marked Leukocytosis: Case Series

Authors:

Fatih Yaman | Filiz Yavaşoğlu | Neslihan Andıc | Eren Gunduz | Hava Üsküdar Teke

Publisher:

Eskişehir Osmangazi University

Main Topics:

Klinik Onkoloji

Journal:

Osmangazi Tıp Dergisi Vol.47 Issue 5, pp.706-711

Document Type:

Article

Publication Date:

4/2025

Document Language:

English

Document ID (Org No.):

2001341768

pISSN:

1305-4953

Keywords:

Abstract:

 Chronic myeloid leukemia CML is a clonal hematopoietic pluripotent stem cell disease characterized by excessive and uncontrolled proliferation of myeloid lineage cells. Platelet count is increased in more than half of patients and the appearance of platelets is variable. When patients present with predominant thrombocytosis without marked leukocytosis, they should be tested for the Philadelphia chromosome or breakpoint cluster region- Abelson BCR-ABL to distinguish cases of CML. In this study, the data of 215 patients diagnosed with CML between 2010 and 2023 were retrospectively evaluated. The study enrolled patients aged 18 years with leukocyte count 40 x109L and platelet count 500 x109L at the time of diagnosis. While investigating the etiology of predominant thrombocytosis and no significant leukocytosis, 13 patients diagnosed with CML were identified. The proportion of these patients among all patients with CML was 6. This study showed that CML should be considered in the differential diagnosis of patients with predominant thrombocytosis without marked leukocytosis. In these patients, the Ph chromosome should definitely be checked before ET is diagnosed. Making a correct diagnosis in this patient group is important in order to start tyrosine kinase inhibitor treatment before it progresses to accelerated or blastic phases.

 Chronic myeloid leukemia CML is a clonal hematopoietic pluripotent stem cell disease characterized by excessive and uncontrolled proliferation of myeloid lineage cells. Platelet count is increased in more than half of patients and the appearance of platelets is variable. When patients present with predominant thrombocytosis without marked leukocytosis, they should be tested for the Philadelphia chromosome or breakpoint cluster region- Abelson BCR-ABL to distinguish cases of CML. In this study, the data of 215 patients diagnosed with CML between 2010 and 2023 were retrospectively evaluated. The study enrolled patients aged 18 years with leukocyte count 40 x109L and platelet count 500 x109L at the time of diagnosis. While investigating the etiology of predominant thrombocytosis and no significant leukocytosis, 13 patients diagnosed with CML were identified. The proportion of these patients among all patients with CML was 6. This study showed that CML should be considered in the differential diagnosis of patients with predominant thrombocytosis without marked leukocytosis. In these patients, the Ph chromosome should definitely be checked before ET is diagnosed. Making a correct diagnosis in this patient group is important in order to start tyrosine kinase inhibitor treatment before it progresses to accelerated or blastic phases.

 Chronic myeloid leukemia CML is a clonal hematopoietic pluripotent stem cell disease characterized by excessive and uncontrolled proliferation of myeloid lineage cells. Platelet count is increased in more than half of patients and the appearance of platelets is variable. When patients present with predominant thrombocytosis without marked leukocytosis, they should be tested for the Philadelphia chromosome or breakpoint cluster region- Abelson BCR-ABL to distinguish cases of CML. In this study, the data of 215 patients diagnosed with CML between 2010 and 2023 were retrospectively evaluated. The study enrolled patients aged 18 years with leukocyte count 40 x109L and platelet count 500 x109L at the time of diagnosis. While investigating the etiology of predominant thrombocytosis and no significant leukocytosis, 13 patients diagnosed with CML were identified. The proportion of these patients among all patients with CML was 6. This study showed that CML should be considered in the differential diagnosis of patients with predominant thrombocytosis without marked leukocytosis. In these patients, the Ph chromosome should definitely be checked before ET is diagnosed. Making a correct diagnosis in this patient group is important in order to start tyrosine kinase inhibitor treatment before it progresses to accelerated or blastic phases.

 Kronik miyeloid lösemi KML, miyeloid seri hücrelerinin aşırı ve kontrolsüz çoğalmasıyla karakterize klonal hematopoietik pluripotent bir kök hücre hastalığıdır. Hastaların yarısından fazlasında trombosit sayısı artmıştır ve trombositlerin görünümü değişkendir. Hastalarda belirgin lökositoz olmaksızın baskın trombositoz mevcutsa, KML vakalarını ayırt etmek için Philadelphia kromozomu veya breakpoint cluster region -Abelson BCR-ABL testi yapılmalıdır. Bu çalışmada 2010-2023 yılları arasında KML tanısı almış 215 hastanın verileri retrospektif olarak değerlendirildi. Çalışmaya tanı anında lökosit sayısı 40 x109L ve trombosit sayısı 500 x109L olan 18 yaş hastalar dahil edildi. Belirgin lökositoz olmadan baskın trombositozla tetkik edilirken KML tanısı alan 13 hasta belirlendi. Bu hastaların tüm KML hastaları içindeki oranı 6 bulundu. Bu çalışma, belirgin lökositoz olmaksızın baskın trombositozu olan hastaların ayırıcı tanısında KMLnin düşünülmesi gerektiğini göstermektedir. Bu hastalarda ET tanısı konulmadan önce mutlaka Ph kromozomuna bakılmalıdır. Bu hasta grubunda doğru tanı koymak, hastalığın akselere veya blastik faza ilerlemeden tirozin kinaz inhibitörü tedavisine başlanması açısından önemlidir.

Article Details

Patients with Chronic Myeloid Leukemia Diagnosed with Predominant Thrombocytosis without Marked Leukocytosis: Case Series

Authors:

Fatih Yaman | Filiz Yavaşoğlu | Neslihan Andıc | Eren Gunduz | Hava Üsküdar Teke

Publisher:

Eskişehir Osmangazi University

Main Topics:

Klinik Onkoloji

Journal:

Osmangazi Tıp Dergisi Vol.47 Issue 5, pp.706-711

Document Type:

Article

Publication Date:

4/2025

Document Language:

English

Document ID (Org No.):

2001341768

pISSN:

1305-4953

chronic myeloid leukemia

myeloproliferative disorders

essential thrombocythemia

thrombosis

tyrosine kinase inhibitorkronik miyeloid lösemi

miyeloproliferatif hastalık

esansiyel trombositoz

tromboz

triozin kinaz inhibitörü

Issues

Article Details

Authors: Fatih Yaman | Filiz Yavaşoğlu | Neslihan Andıc | Eren Gunduz | Hava Üsküdar Teke

Publisher: Eskişehir Osmangazi University

Main Topics: Klinik Onkoloji

Journal: Osmangazi Tıp Dergisi Vol.47 Issue 5, pp.706-711

Document Type: Article

Publication Date: 4/2025

Document Language: English

Document ID (Org No.): 2001341768

pISSN: 1305-4953

Issues

Authors:

Fatih Yaman | Filiz Yavaşoğlu | Neslihan Andıc | Eren Gunduz | Hava Üsküdar Teke

Publisher:

Eskişehir Osmangazi University

Main Topics:

Klinik Onkoloji

Journal:

Osmangazi Tıp Dergisi Vol.47 Issue 5, pp.706-711

Document Type:

Article

Publication Date:

4/2025

Document Language:

English

Document ID (Org No.):

2001341768

pISSN:

1305-4953